SCHEMBL1440765

SCHEMBL1440765

CC(=O)c1cc(N)ccc1F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.44
ALDH1A1 P00352 4/20 0.44
KDM4E B2RXH2 4/20 0.44
TDP1 Q9NUW8 3/20 0.44
MEN1 O00255 3/20 0.44
THRB P10828 3/20 0.44
KMT2A Q03164 3/20 0.44
RECQL P46063 2/20 0.44
CYP3A4 P08684 2/20 0.44
POLB P06746 2/20 0.44
ALOX15 P16050 2/20 0.44
HSD17B10 Q99714 2/20 0.44
USP2 O75604 1/20 0.44
PKM P14618 1/20 0.44
APEX1 P27695 1/20 0.44
BLM P54132 1/20 0.44
MCL1 Q07820 1/20 0.44
TNF P01375 1/20 0.44
HSPD1 P10809 1/20 0.44
CYP2C9 P11712 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30476086 0.83 MAOB (0.45) MAPTALDH1A1KDM4ETDP1MEN1
SCHEMBL8280039 0.83 MAOB (0.45) MAPTALDH1A1KDM4ETDP1MEN1
SCHEMBL30925630 0.81 KDM4E (0.61) MAPTALDH1A1KDM4ETDP1MEN1
SCHEMBL3079582 0.81 MAPT (0.49) MAPTALDH1A1KDM4ETDP1MEN1
SCHEMBL416879 0.81 KDM4E (0.61) MAPTALDH1A1KDM4ETDP1MEN1
SCHEMBL26054237 0.80 MAPT (0.48) MAPTALDH1A1KDM4ETDP1MEN1
SCHEMBL30311840 0.80 MAPT (0.48) MAPTALDH1A1KDM4ETDP1MEN1
SCHEMBL24180500 0.79 ALDH1A1 (0.52) MAPTALDH1A1KDM4ETDP1MEN1
Hydrochloric Acid SCHEMBL6984724 0.79 KMT2A (0.64) MAPTALDH1A1KDM4ETDP1MEN1
Hydrochloric Acid SCHEMBL20639113 0.79 MAPT (0.48) MAPTALDH1A1KDM4ETDP1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024217557-A1 SUBSTITUTED TETRAHYDROFURANS AS NAV1.8 INHIBITORS 武汉人福创新药物研发中心有限公司 2024-10-24 WO disclosed
CN-118812519-A Substituted tetrahydrofurans as Nav1.8 inhibitors 武汉人福创新药物研发中心有限公司 2024-10-22 CN disclosed
US-20230357165-A1 QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2023-11-09 US disclosed
US-20230357165-A1 QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2023-11-09 US disclosed
US-20230303497-A1 BENZYLAMINE OR BENZYL ALCOHOL DERIVATIVE AND USES THEREOF CHENGDU HYPERWAY PHARMACEUTICALS CO., LTD (CN) 2023-09-28 US disclosed
US-20230303497-A1 BENZYLAMINE OR BENZYL ALCOHOL DERIVATIVE AND USES THEREOF CHENGDU HYPERWAY PHARMACEUTICALS CO., LTD (CN) 2023-09-28 US disclosed
US-20230303497-A1 BENZYLAMINE OR BENZYL ALCOHOL DERIVATIVE AND USES THEREOF CHENGDU HYPERWAY PHARMACEUTICALS CO., LTD (CN) 2023-09-28 US disclosed
EP-4230618-A1 BENZYLAMINE OR BENZYL ALCOHOL DERIVATIVE AND USE THEREOF Chengdu Hyperway Pharmaceuticals Co., Ltd. (CN) 2023-08-23 EP disclosed
EP-4230618-A1 BENZYLAMINE OR BENZYL ALCOHOL DERIVATIVE AND USE THEREOF Chengdu Hyperway Pharmaceuticals Co., Ltd. (CN) 2023-08-23 EP disclosed
CN-114031518-B Benzylamine or benzyl alcohol derivative and application thereof 成都海博为药业有限公司 2023-08-18 CN disclosed
US-5360822-A FOR TREATING URINARY INCONTINENCE IN ANIMALS AND HUMANS NIPPON SHINYAKU CO. LTD. (JP) 1994-11-01 US disclosed
EP-0538469-A1 SULFONANILIDE DERIVATIVE AND MEDICINE NIPPON SHINYAKU COMPANY, LIMITED (JP) 1993-04-28 EP disclosed
US-4777175-A (NAPHTHYRIDINE, QUINOLINE) CARBOXYLIC ACID WARNER-LAMBERT COMPANY (US) 1988-10-11 US disclosed
US-4771054-A QUINOLINE CARBOXYLIC ACID WARNER-LAMBERT COMPANY (US) 1988-09-13 US disclosed
EP-0106489-B1 ANTIBACTERIAL AGENTS WARNER-LAMBERT COMPANY (US) 1988-07-27 EP disclosed
US-4665079-A QUINOLINE DERIVATIVES WARNER-LAMBERT COMPANY (US) 1987-05-12 US disclosed
US-4638067-A NAPHTHYRIDINE AND QUINOLINE CARBOXYLIC ACIDS WARNER-LAMBERT CO. (US) 1987-01-20 US disclosed
EP-0153163-A2 7-Substituted-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids; 7-substituted-1-cyclopropyl-1,4-dihydro-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acids; their derivatives; and a process for preparing the compounds WARNER-LAMBERT COMPANY (US) 1985-08-28 EP disclosed
EP-0106489-A2 Antibacterial agents WARNER-LAMBERT COMPANY (US) 1984-04-25 EP disclosed
US-4145364-A PREPARATION OF FLUORINATED ANILINES MERCK & CO., INC. (US) 1979-03-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357165-A1 QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF ATG7, GOT1, LIPC MAPT 2243/4885ALDH1A1 295/4885KDM4E 1291/4885
US-20230303497-A1 BENZYLAMINE OR BENZYL ALCOHOL DERIVATIVE AND USES THEREOF SCN8A, SCN9A, SCN10A MAPT 1923/4885ALDH1A1 1050/4885KDM4E 1134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.